18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
Sponsor: Children's Hospital of Philadelphia
ClinicalTrials ID:NCT01916148
This study evaluates the use of 18F-DOPA PET scans to detect focal lesions in patients with hyperinsulinemic hypoglycemia, aiding surgical planning. Eligible participants include those of any age with the condition, suitable for pancreatic surgery. Exclusions are pregnant/lactating females and those with major illnesses. The intervention involves using 18F-DOPA as a PET scan radiotracer.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This purpose of this study is to determine the ability of an 18F-fluoro-L-dihydroxyphenylalanine (18F-DOPA) PET (Positron Emission Tomography) scan to detect a focal lesion of hyperinsulinism and determine the location in patients with congenital hyperinsulinism, Beckwith Wiedemann Syndrome and suspected insulinoma. Safety data will be collected.
Description
Patients with hyperinsulinemic hypoglycemia are at risk for neurological damage due to hypoglycemia. Early surgical intervention can be preventative. F-DOPA PET may be able to detect of a focal lesion prior to surgical intervention and be used during surgical planning to guide the surgical procedure.
Eligibility Criteria
Inclusion Criteria
- Subjects of any age with hyperinsulinemic hypoglycemia, diagnosed by a fasting test and/or response to glucagon stimulation.
- Subjects who are eligible for pancreatic surgery regardless of prior pancreatic surgery
Exclusion Criteria
- Pregnant or lactating females
- Any other major illness or condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in this study
- Subjects who are not a candidate for pancreatic surgery
Get This Program In Your Inbox
You can sign up and apply your patients for this program.